I just read all of your comments in vp, and I must confess, I am thoroughly impressed with your thinking approach. I enjoy the way you see the market. Seems logical/mature to me.
I guess, I need to develop the above approach inside me to be a better investor. Keep guiding
Also, please introduce yourself in valuepickr introduction thread.
Very nice thought process Surya but the difference of 30% and 60% is doubling money in 1 year 1yr and a quarter and 2 and a half years. Conviction level again is a unmeasured parameter which cannot be baselined.
I tried to collect my thoughts on âConvictionâ. Conviction is actually a metaphor. I can say like this High Conviction is a possibility which has highest probability. And moreover you need to know on what you need conviction. Do you need conviction on the price you are paying, or on the market size, or on the management quality etc. If you are an investor like me then the first thing you need conviction is on Market size. Because scalability is what I look for mostly. If they say 60000 cr drug retailing Market what is important is you need to know whether it is really big or not. There is no need to validate on 60000 cr number.
You can list out on what you need to have conviction and then take it from there. **The main thing is you need to have a broader picture first and then financials may help in making reasonable judgements. **
I would recommend a book here. âInnumeracyâ by John Allen Paulos for a treat on making âreasonable judgementsâ.
Around one and half month back you told me to hold Astral & Cera,You also told me âthere is no reason selling a 30-35% compounder because of illusion of high valuation (if you consider next qtr result, trailing pe is 24, which I think is fairly valued for 30%+ compounder).â
Then you were absolutely right,Astral Poly,the stock has had a great rally again from the 380 levels to 500 since then & Cera,this stock also has had massive rally again from 750 to 900 doesnât seems stopping,My query is Astral & Cera,this two stocks,isnât it bit expensive? Or should we view this as re-rating after Q4 result,Beside this we know that Astral & Cera is an excellent business,what do you sayâŚ& are you still happy to hold this businesses?
Besides, if you have read a post of Bakshi, where he mention how investing Nestle at its peak valuation, still gives decent return in long run. So, the lesson for me from the above article is to just invest in quality/branded/consumption themed play at right price, and do nothing. Doing nothing is an excellent, but under appreciated strategy. People have forgotten this lesson in Page, and have gotten out of it, and hence could not reap the full compounding benefit.
Just enjoy the ride in eps/price/brand/business for next 5-10 yrs is the strategy for me when come to astral/cera. I have no plan to sell them unless they become extremely over-valued (and feel better return expectation in non-equity side like real estate in next 4-5 yr), and I see they are far far away from the extreme over-valuation range.
Around one and half month back you told me to hold Astral & Cera,You also told me âthere is no reason selling a 30-35% compounder because of illusion of high valuation (if you consider next qtr result, trailing pe is 24, which I think is fairly valued for 30%+ compounder).â
Then you were absolutely right,Astral Poly,the stock has had a great rally again from the 380 levels to 500 since then & Cera,this stock also has had massive rally again from 750 to 900 doesnât seems stopping,My query is Astral & Cera,this two stocks,isnât it bit expensive? Or should we view this as re-rating after Q4 result,Beside this we know that Astral & Cera is an excellent business,what do you sayâŚ& are you still happy to hold this businesses?
Subashji,Thanks for your reply.this is quite a lesson for meâŚ
@Manish - Various Pharma related stocks that I have have different (and uncorrelated) business characteristics, and hence I donât feel it make sense to club them into a single group.
Ajanta is mostly emerging market play (not effected by stringent USFDA), Aurobindo is turnaround US ANDA play (can get adversly effected by USFDA rulling), Shilpa is predominantly an Onco API play, which is getting positively impacted by stringent USFDA (as other players are increasingly dependent on its API). Alembic is an excellent growth story, with increasing portion of US/Export in sales.
@Rajat - I needed money for paying part of my home loan installment, and hence sold repco/pi in that process.
Dirt cheap valuation, promoter buying from open market, transition to hardware solution business to an asset light model, Mcap == cash.
I have taken an initial starter position in hcl info. Planning to increase stake in SIP manner. It has been the case for almost all of my buying (I buy small chunks of stocks I like in SIP basis most of the time)
Can you please explain more about transition to hardware solution business to an asset light model? I didnât understand this part⌠I want to know what is the change in business strategy that will bring growthâŚ